OPR - Delayed Quote • USD ANVS Jul 2024 30.000 call (ANVS240719C00030000) Follow 5.65 +1.45 (+34.52%) At close: April 26 at 11:32 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for ANVS240719C00030000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ANVS Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag Eyenovia (EYEN) Down 18% on Disappointing Corporate Update Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
